
































The FAITH and HEALTH Trials: Are We Studying Different
Hip Fracture Patient Populations?
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Daniel Axelrod, MD, MSc (Cand),c Rudolf W. Poolman, MD, PhD,d Frede Frihagen, MD, PhD, FRCSC,e
Mohit Bhandari, MD, PhD, FRCSC,c,f Marc Swiontkowski, MD,g Sheila Sprague, PhD,c,f
and Patrick C. Schottel, MDa on behalf of the FAITH and HEALTH Investigators
Background: Over the past decade, 2 randomized controlled trials
were performed to evaluate 2 surgical strategies (internal fixation and
arthroplasty) for the treatment of low-energy femoral neck fractures
in patients aged $50 years. We evaluated whether patient popula-
tions in both the FAITH and HEALTH trials had different baseline
characteristics and compared the displaced femoral neck fracture
cohort from the FAITH trial to HEALTH trial patients.
Methods: Patient demographics, medical comorbidities, and frac-
ture characteristics from both trials were compared. FAITH trial
patients with displaced fractures were then compared with HEALTH
patients. T-tests and x2 tests were performed to compare differences
for sex, age, osteoporosis status, and ASA class.
Results: The mean age of the 1079 FAITH trial patients was 72
versus 79 years for the 1441 HEALTH trial patients. HEALTH
patients were older, mostly White, used more medication, and had
more comorbidities than FAITH patients. Of the 1079 FAITH trial
patients, 32% (346/1079) had displaced fractures. Their mean age
was significantly lower than that of HEALTH patients (66 vs. 79
years; P , 0.001). HEALTH trial patients were significantly more
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likely to be female, have ASA classification Class III/IV/V, and carry
a diagnosis of osteoporosis, as compared with the subgroup of
FAITH patients with displaced femoral neck fractures (P , 0.001).
Conclusion: This study demonstrates significant differences
between patients enrolled in the 2 trials. Although both studies
focused on femoral neck fractures with similar enrollment criteria,
patient populations differed. This sheds light on a noteworthy
limitation of discordant patient enrollment into randomized trials,
despite similar eligibility criteria.
Key Words: baseline characteristics, femoral neck fracture
Level of Evidence: Therapeutic Level II. See Instructions for
Authors for a complete description of levels of evidence.
(J Orthop Trauma 2020;34:S1–S8)
INTRODUCTION
Significant controversies exist regarding the ideal
treatment of undisplaced and displaced femoral neck fractures
in both the young and geriatric populations. In young
patients, internal fixation is typically employed to preserve
a healthy functional hip joint. Although arthroplasty out-
comes are quite predictable and successful, revision surgery is
occasionally needed due to issues such as component
loosening, instability, adverse tissue reaction, periprosthetic
fractures, and infections.1 When hip arthroplasty is performed
in young patients, the lifetime risk of revision is higher, and
the poor success rates of those revisions are problematic.2 In
the elderly population, arthroplasty is the mainstay of treat-
ment, especially in patients with displaced fractures.
Intriguingly, recent studies suggest that in elderly patients,
even undisplaced and minimally displaced fractures can have
improved clinical outcomes with arthroplasty as compared
with internal fixation.3–5
When considering both internal fixation and replace-
ment, the ideal implant choice remains controversial. The
FAITH trial randomized patients with both undisplaced and
displaced femoral neck fractures to receive either cancellous
screws or a sliding hip screw.6 The HEALTH trial random-
ized patients with displaced femoral neck fractures to either a
hemiarthroplasty or a total hip replacement.7 Both studies
enrolled patients aged 50 years and older with a low-energy
fracture mechanism. Patient enrollment eligibility criteria of
both studies are displayed in Table 1. However, the extent of
similarity of patients who were actually enrolled in both stud-
ies is not known. The aim of this study was to evaluate
whether the patient populations enrolled into both multicenter
trials were different from one another in respect to demo-
graphics and medical comorbidities. Furthermore, we specif-
ically compared the displaced femoral neck fractures that
were treated with internal fixation in the FAITH trial with
the HEALTH trial patients. We hypothesized that the 2 study
populations would be similar.
METHODS
Baseline demographics and fracture characteristics of
all enrolled patients from both the FAITH and HEALTH trials
were compared. Factors included were age, sex, ethnicity,
TABLE 1. FAITH and HEALTH Trials Patient Enrollment
Eligibility Criteria
FAITH Inclusion Criteria HEALTH Inclusion Criteria
Adult men or women aged 50 years
and older (with no upper age limit)
Adult men or women aged 50
years and older (with no upper
age limit)
Fracture of the femoral neck
confirmed with either AP or lateral
hip radiographs, CT, MRI
Fracture of the femoral neck
confirmed with either AP or lateral
hip radiographs, CT, MRI
Operative treatment of displaced
fractures within 4 days of presenting
to the emergency room
Displaced fracture that is not, in the
judgment of the attending surgeon,
optimally managed by reduction and
internal fixation
Operative treatment of undisplaced
fractures within 7 days of presenting
to the ER
Operative treatment within 3 days of
the patient being medically cleared
for surgery
Patient was ambulatory before
fracture, although they may have
used an aid such as a cane or a
walker
Patient was ambulatory before
fracture, although they may have
used an aid such as a cane or a
walker
Anticipated medical optimization for
operative fixation of the hip
Anticipated medical optimization for
arthroplasty of the hip
Provision of informed consent by
patient or legal guardian
Provision of informed consent by
patient or proxy
Low-energy fracture, in the
judgment of the attending surgeon
Low-energy fracture (defined as a
fall from standing height)
No other major trauma (defined as
an injury severity score .16)
No other major trauma (defined as
an injury severity score ,17)
Assurance that surgeons with
expertise in both total hip
arthroplasty and hemiarthroplasty
were available to perform surgery
FAITH Exclusion Criteria HEALTH Exclusion Criteria
Patients not suitable for internal
fixation (ie, severe osteoarthritis,
rheumatoid arthritis, or pathologic
fracture)
Patient not suitable for
hemiarthroplasty (eg, inflammatory
arthritis, RA, pathologic fracture, or
severe hip OA)
Associated major injuries of the
lower extremity (ie, ipsilateral or
contralateral fractures of the foot,
ankle, tibia, fibula, knee, or femur;
dislocations of the ankle, knee, or
hip; or femoral head defects or
fracture)
Associated major injuries of the
lower extremity (ie, ipsilateral or
contralateral fractures of the foot,
ankle, tibia, fibula, knee, or femur;
dislocations of the ankle, knee, or
hip; or femoral head defects or
fracture)
Retained implant around the affected
hip
Retained implant around the affected
hip
Infection around the hip (ie, soft
tissue/bone)
Infection around the hip (soft tissue
or bone)
Patients with disorders of known
bone metabolism except
osteoporosis (ie, Paget disease, renal
osteodystrophy, osteomalacia)
Patients with a disorder of bone
metabolism other than osteoporosis
(ie, Paget disease, renal
osteodystrophy, osteomalacia)
Patients with a history of frank
dementia that would interfere with
assessment of the primary outcome
(ie, reoperation at 2 years)
Patients with a previous history of
frank dementia that would interfere
with assessment of the primary
outcome (ie, secondary procedures
at 2 years)
Likely problems, in the judgment of
the investigators, with maintaining
follow-up
Likely problems, in the judgment of
the investigators, with maintaining
follow-up
Patients whose fracture occurred as a
result of an act of violence
AP, anteroposterior; CT, computerized tomography; MRI, magnetic resonance
imaging; OA, osteoarthritis; RA, rheumatoid arthritis.
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body mass index (BMI), prefracture living status and
functional status, medications, and major comorbidities. All
patients enrolled in the HEALTH trial had a displaced
femoral neck fracture (Garden III and IV).8 The FAITH trial
patients were divided using the Garden classification between
undisplaced (Garden I and II) and displaced (Garden III and
IV) fractures. The FAITH trial patients with displaced frac-
tures were then separately compared with the HEALTH
patients. To assess severity of fracture displacement in each
trial, the numbers of patients with Garden III and IV fractures
in each trial were also compared.
Statistical Analysis
Statistical analysis using t-tests and x2 tests were then used
to compare the differences for the following factors using the a
priori principle: sex, age, osteoporosis status, and American
Society of Anesthesiologists (ASA) class. To avoid multiple
comparisons, given the large numbers of variables collected in
each study, the authors elected to statistically analyze only the 4
fundamental factors above. All tests were 2 tailed with alpha =
0.05. Continuous data were presented with means and SDs, and
categorical data were presented as frequencies and proportions.
RESULTS
The mean age of the 1079 patients in the FAITH trial
was 72 (SD, 12) years, as opposed to 79 (SD, 8) years for the
1441 patients in the HEALTH trial. The HEALTH patients
were older, more often White and less ethnically diverse, used
more medication, and had more comorbidities. Table 2 sum-
marizes all the patient demographic comparisons between the
FAITH and HEALTH trial participants.
The fracture characteristics of FAITH and HEALTH trial
patients are summarized in Table 3. Of the 1079 patients in the
FAITH trial, 32% (346/1079) of the patients had displaced
fractures. Of these displaced fracture patients, 72% were clas-
sified as Garden 3, as opposed to 44% in the HEALTH trial.
Tables 4 and 5 summarize the demographic and fracture char-
acteristics of the displaced fracture patients from the FAITH
trial as compared with the HEALTH trial patients.
Comparison of selected characteristics of displaced
fracture patients in the FAITH and HEALTH trials found
that the mean age of the HEALTH study patients was
significantly higher than that of the patients in the FAITH
study (79 vs. 66 years; P , 0.001). The HEALTH trial
patients were significantly more likely to be female, have
ASA classification Class III/IV/V, and have a known diagno-
sis of osteoporosis, as compared with the subgroup of FAITH
patients with displaced femoral neck fractures (P , 0.001).
Table 6 summarizes the subgroup comparisons.
DISCUSSION
Although the inclusion criteria for both the FAITH and
HEALTH studies were very similar and included patients older
than 50 years who sustained low-energy femoral neck fractures,
this study critically evaluated the patients who were actually
enrolled in both studies. Overall, the HEALTH patients were
older, more often White and less ethnically diverse, used more
medication, and had more comorbidities than the FAITH
patients. When specifically comparing the patients with dis-
placed fractures from the FAITH trial with those in the
HEALTH study, we found that HEALTH study patients were
significantly older, more often female, were ASA Class III/IV/
V, and had osteoporosis. This demonstrates that there was
unintentional discordant patient enrollment despite nearly
identical inclusion and exclusion criteria. It is conceivable that
surgeons were less likely to enroll unhealthy older patients with
any fracture displacement in an internal fixation trial.
The importance of scrutinizing a trial’s inclusion and
exclusion criteria, as well as the subsequently enrolled study
cohort cannot be overstated. Not appreciating the sometimes
subtle exclusion of a specific patient population from a study
can lead to findings that result in potentially unintended
changes in surgical practice. For instance, a 2015 landmark
study, Proximal Fracture of the Humerus Evaluation by
Randomization (PROFHER), prospectively randomized dis-
placed proximal humerus fracture patients aged 16 years and
older between operative and nonoperative management.9
They found that operative management provided no patient-
reported clinical outcome benefit compared with nonoperative
treatment. This has understandably led to greater interest in
nonoperative management of displaced proximal humerus
fractures. However, it is important to note that of the 1250
patients assessed for study eligibility, there were 1000
patients who were excluded using rationale such as “clear
indication for surgery” and “other reasons.” Having broad
inclusion criteria, as well as exclusion criteria that give a
surgeon the ability to not enroll patients based on their per-
sonal discretion can have unintentional consequences, such as
often overlooked selection bias. In the FAITH trial, it was
reported that 21% of patients required a revision within 24
months of their index surgery. Although a 21% revision rate
is relatively acceptable for internal fixation in a geriatric fem-
oral neck fracture cohort, it is easy to overlook that the study
enrolled a disproportionate number of undisplaced fractures
(68%; 733/1079). Overlooking that important point may
result in misinterpreting the findings and concluding that
internal fixation of all geriatric femoral neck fractures is suc-
cessful in approximately 80% of patients. If a more represen-
tational geriatric femoral neck fracture population had been
enrolled, it is likely that the revision rate would have been
higher. One proposal would be to obtain a general consensus
for standard study inclusion and exclusion criteria. Leaving
enrollment criteria up to the investigator or surgeon enrolling
the patient can oftentimes introduce unintended selection
bias. Greater focus on this aspect of study design is needed.
Patients’ age was highlighted to be a significant differ-
ence between the patients enrolled in both the HEALTH and
FAITH studies. In a recent systematic review and meta-
analysis of internal fixation versus arthroplasty for the treat-
ment of nondisplaced femoral neck fractures in the elderly,
patients’ average age was approximately 80 years. The review
concluded that when treating nondisplaced and minimally
displaced femoral neck fractures in the elderly, hemiarthro-
plasty may reduce the relative risk of reoperation by 70%
when compared with internal fixation. Nevertheless, the
authors proposed that their results are most applicable to
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TABLE 2. Patient Demographics in FAITH and HEALTH Trials
Characteristic CS, n = 537 SHS, n = 542 THA, n = 718 HA, n = 723
Age, mean (SD) n = 537 n = 542 n = 718 n = 722
72.0 (12.3) 72.2 (12.0) 79.1 (8.3) 78.6 (8.6)
Age, n (%) n = 535 n = 535 n = 718 n = 722
50–70 y 238 (44.5) 245 (45.8) 136 (18.9) 149 (20.6)
71–80 y 147 (27.5) 138 (25.8) 249 (34.7) 247 (34.2)
$81 y 150 (28.0) 152 (28.4) 333 (46.4) 326 (45.1)
Sex, n (%) n = 535 n = 535 n = 718 n = 722
Male 210 (39.3) 212 (39.6) 208 (29.0) 223 (30.9)
Female 325 (60.7) 323 (60.4) 510 (71.0) 499 (69.1)
Ethnicity, n (%) n = 535 n = 533 n = 716 n = 721
Indigenous 3 (0.6) 1 (0.2) 2 (0.3) 1 (0.1)
South Asian 65 (12.1) 65 (12.2) 3 (0.4) 6 (0.8)
East Asian 4 (0.7) 6 (1.1) 7 (1.0) 7 (1.0)
Hispanic/Latino 1 (0.2) 3 (0.6) 7 (1.0) 6 (0.8)
White 444 (83.0) 436 (81.8) 683 (95.4) 684 (94.9)
Black 18 (3.4) 22 (4.1) 12 (1.7) 15 (2.1)
Middle Eastern 0 (0.0) 0 (0.0) 2 (0.3) 2 (0.3)
BMI (kg/m2), n (%) n = 528 n = 530 n = 697 n = 705
Underweight ,18.5 33 (6.3) 37 (7.0) 35 (5.0) 38 (5.4)
Normal weight 18.5–24.9 300 (56.8) 276 (52.1) 357 (51.2) 336 (47.7)
Overweight 25–29.9 148 (28.0) 159 (30.0) 217 (31.1) 243 (34.5)
Obese 30–39.9 47 (8.9) 58 (10.9) 77 (11.1) 83 (11.8)
Morbidly obese $40 0 (0.0) 0 (0.0) 11 (1.6) 5 (0.7)
Prefracture living status, n (%) n = 537 n = 542 n = 718 n = 723
Institutionalized 31 (5.8) 30 (5.5) 30 (4.2) 27 (3.7)
Not institutionalized 506 (94.2) 512 (94.5) 688 (95.8) 696 (96.3)
Pre-fracture functional status, n (%) n = 537 n = 542 n = 718 n = 723
Use of Aid 110 (20.5) 121 (22.3) 187 (26.0) 182 (25.2)
Independent ambulator 427 (79.5) 421 (77.7) 531 (74.0) 541 (74.8)
Current medications, n (%) n = 534 n = 535 n = 715 n = 722
None 179 (33.5) 170 (31.8) 114 (15.9) 127 (17.6)
NSAIDs 64 (12.0) 86 (16.1) 91 (12.7) 90 (12.5)
Analgesics: opioid 69 (12.9) 58 (10.8) 63 (8.8) 55 (7.6)
Glucocorticoids Not collected Not collected 26 (3.6) 23 (3.2)
Anabolic steroid therapy Not collected Not collected 3 (0.4) 1 (0.1)
Hormone replacement therapy Not collected Not collected 30 (4.2) 34 (4.7)
Bisphosphonates Not collected Not collected 50 (7.0) 47 (6.5)
Other osteoporosis medications 73 (13.6) 67 (12.5) 28 (3.9) 15 (2.1)
Anti-hypertension medications 252 (47.1) 244 (45.6) 407 (56.9) 402 (55.7)
Pulmonary (respiratory system) 69 (12.9) 58 (10.8) 81 (11.3) 87 (12.1)
Medications
General cardiac medications 167 (31.2) 167 (31.2) 296 (41.4) 278 (38.5)
Calcium Not collected Not collected 140 (19.6) 139 (19.3)
Calcitonin (mialcalcin) Not collected Not collected 2 (0.3) 1 (0.1)
Vitamin D Not collected Not collected 165 (23.1) 160 (22.2)
Prior surgery to affected hip, n (%) N = 535 N = 535 N = 714 N = 722
0 (0) 3 (0.6) 2 (0.3) 1 (0.1)
Major comorbidities, n (%) N = 537 N = 542 N = 715 N = 722
Osteopenia Not collected Not collected 28 (3.9) 30 (4.2)
Osteoporosis 19 (3.5) 14 (2.6) 114 (15.9) 110 (15.2)
Lung disease 103 (19.2) 87 (16.1) 127 (17.8) 122 (16.9)
Diabetes 79 (14.7) 82 (15.1) 135 (18.9) 145 (20.1)
Ulcers or stomach disease 81 (15.1) 68 (12.5) 49 (6.9) 67 (9.3)
Kidney disease 58 (10.8) 34 (6.3) 71 (9.9) 67 (9.3)
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patients in their late 70s and 80s and may not be generalizable
to younger patients.5 Likewise, our study reveals that the
overall results of both the FAITH and HEALTH trials might
be applicable to dissimilar age groups. The significantly lower
age in the FAITH group would suggest that surgeons are
more likely to consider or attempt internal fixation of dis-
placed femoral neck fractures in younger healthy male
subjects.
The patients enrolled in the HEALTH trial were more
often White and less ethnically diverse than the FAITH patient
population. The lack of diversity in patient enrollment for
orthopaedic studies should not go unnoticed. A systematic
review of orthopaedic randomized controlled trials published
from 2008 to 2011 highlighted this trend.10 Few orthopaedic
randomized controlled trials performed in the United States
reported information on patients’ race or ethnicity. Among
trials that reported demographic race/ethnicity data, the inclu-
sion of minority patients was considerably lower than would be
anticipated on the basis of census demographics. Failure to
represent racial diversity may result in decreased generalizabil-
ity of study conclusions across different populations. Bias
against patients with dementia was also recently recognized
as a concern because patients with dementia and hip fractures
often get excluded from clinical trials. In the FAITH study, a
total of 1690 patients were excluded, 22.2% (375/1690) due to
dementia or cognitive impairment. In the HEALTH study, 36%
TABLE 2. (Continued ) Patient Demographics in FAITH and HEALTH Trials
Characteristic CS, n = 537 SHS, n = 542 THA, n = 718 HA, n = 723
Anemia or other blood disease 55 (10.2) 40 (7.4) 48 (6.7) 55 (7.6)
Depression 92 (17.1) 76 (14.0) 70 (9.8) 84 (11.6)
Cancer 63 (11.7) 59 (10.9) 65 (9.1) 80 (11.1)
Osteoarthritis, degenerative
arthritis
121 (22.5) 160 (29.5) 111 (15.5) 91 (12.6)
Back pain 104 (19.4) 106 (19.6) 64 (9.0) 71 (9.9)
Rheumatoid arthritis 26 (4.8) 6 (1.1) 13 (1.8) 21 (2.9)
Heart disease 157 (29.2) 156 (28.8) 247 (34.6) 249 (34.5)
High blood pressure 276 (51.4) 281 (51.8) 434 (60.7) 443 (61.4)
BMI, body mass index; CS, cancellous screws; HA, hemiarthroplasty; NSAIDS, nonsteroidal anti-inflammatory drugs; SHS, sliding hip screw; THA, total hip arthroplasty.
TABLE 3. Fracture Characteristics in FAITH and HEALTH Trials
Characteristic CS, n = 537 SHS, n = 542 THA, n = 718 HA, n = 723
Fractured hip, n (%) n = 535 n = 535 n = 715 n = 722
Left 281 (52.5) 280 (52.3) 386 (54.0) 386 (53.5)
Right 254 (47.5) 255 (47.7) 329 (46.0) 336 (46.5)
Level of the fracture line, n (%) n = 536 n = 535 n = 715 n = 722
Subcapital 351 (65.5) 331 (61.9) 434 (60.7) 456 (63.2)
Midcervical 154 (28.7) 159 (29.7) 251 (35.1) 230 (31.9)
Basal 31 (5.8) 45 (8.4) 30 (4.2) 36 (5.0)
Garden classification, n (%) n = 537 n = 542 n = 715 n = 722
Garden I (undisplaced) 277 (51.7) 257 (48.0) N/A N/A
Garden II (undisplaced) 92 (17.2) 99 (18.5) N/A N/A
Garden III (displaced) 128 (23.9) 121 (22.6) 311 (43.5) 320 (44.3)
Garden IV (displaced) 39 (7.3) 58 (10.8) 404 (56.5) 402 (55.7)
Pauwels’ classification, n (%) n = 536 n = 535 n = 714 n = 721
Type I 59 (11.0) 59 (11.0) 70 (9.8) 47 (6.5)
Type II 394 (73.5) 398 (74.4) 404 (56.6) 367 (50.9)
Type III 83 (15.5) 78 (14.6) 240 (33.6) 307 (42.6)
Mechanism of injury, n (%) n = 534 n = 533 n = 715 n = 722
Fall from standing 521 (97.6) 515 (96.7) 696 (97.3) 700 (97.0)
Spontaneous fracture 6 (1.1) 13 (2.4) 16 (2.2) 14 (1.9)
Fall from small height Not collected Not collected 3 (0.4) 8 (1.1)
Other low energy trauma 7 (1.3) 5 (0.9) Not collected Not collected
Additional fractures or injuries, n (%) n = 535 n = 535 n = 714 n = 722
72 (13.5) 67 (12.5) 61 (8.5) 60 (8.3)
CS, cancellous screws; HA, Hemi-arthroplasty; SHS, sliding hip screw; THA, total hip arthroplasty.
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TABLE 4. Demographics of Displaced Fracture Patients in FAITH and HEALTH Trials
Characteristic CS, n = 167 SHS, n = 179 THA, n = 718 HA, n = 723
Age, mean (SD) n = 166 n = 179 n = 718 n = 722
66.1 (11.5) 67.7 (11.1) 79.1 (8.3) 78.6 (8.6)
Age, n (%) n = 166 n = 179 n = 718 n = 722
50–70 y 107 (64.1) 111 (62.0) 136 (18.9) 149 (20.6)
71–80 y 41 (24.6) 42 (23.5) 249 (34.7) 247 (34.2)
$81 y 18 (10.8) 26 (14.5) 333 (46.4) 326 (45.1)
Sex, n (%) n = 166 n = 179 n = 718 n = 722
Male 92 (55.1) 98 (54.7) 208 (29.0) 223 (30.9)
Female 74 (44.3) 81 (45.3) 510 (71.0) 499 (69.1)
Ethnicity, n (%) n = 166 n = 179 n = 716 n = 721
Indigenous 2 (1.2) 1 (0.6) 2 (0.3) 1 (0.1)
South Asian 40 (24.0) 41 (22.9) 3 (0.4) 6 (0.8)
East Asian 1 (0.6) 1 (0.6) 7 (1.0) 7 (1.0)
Hispanic/Latino 1 (0.6) 0 (0.0) 7 (1.0) 6 (0.8)
White 120 (71.9) 133 (74.3) 683 (95.4) 684 (94.9)
Black 2 (1.2) 3 (1.7) 12 (1.7) 15 (2.1)
Middle Eastern 0 (0.0) 0 (0.0) 2 (0.3) 2 (0.3)
BMI (kg/m2), n (%) n = 164 n = 174 n = 697 n = 705
Underweight ,18.5 7 (4.2) 8 (4.5) 35 (5.0) 38 (5.4)
Normal weight 18.5–24.9 85 (50.9) 90 (50.3) 357 (51.2) 336 (47.7)
Overweight 25–29.9 54 (32.3) 60 (33.5) 217 (31.1) 243 (34.5)
Obese 30–39.9 16 (9.6) 14 (7.8) 77 (11.1) 83 (11.8)
Morbidly obese $40 2 (1.2) 2 (1.1) 11 (1.6) 5 (0.7)
Pre-fracture living status, n (%) n = 167 n = 179 n = 718 n = 723
Institutionalized 5 (3.0) 12 (6.7) 30 (4.2) 27 (3.7)
Not institutionalized 162 (97.0) 167 (93.3) 688 (95.8) 696 (96.3)
Pre-fracture functional status, n (%) n = 167 n = 179 n = 718 n = 723
Use of Aid 18 (10.8) 30 (16.8) 187 (26.0) 182 (25.2)
Independent Ambulator 149 (89.2) 149 (83.2) 531 (74.0) 541 (74.8)
Current medications, n (%) n = 166 n = 179 n = 715 n = 722
None 87 (52.1) 78 (43.6) 114 (15.9) 127 (17.6)
NSAIDs 17 (10.2) 37 (20.7) 91 (12.7) 90 (12.5)
Analgesics: Opioid 6 (3.6) 9 (5.0) 63 (8.8) 55 (7.6)
Glucocorticoids Not collected Not collected 26 (3.6) 23 (3.2)
Anabolic steroid therapy Not collected Not collected 3 (0.4) 1 (0.1)
Hormone replacement therapy Not collected Not collected 30 (4.2) 34 (4.7)
Bisphosphonates Not collected Not collected 50 (7.0) 47 (6.5)
Other osteoporosis medications 12 (7.2) 15 (8.4) 28 (3.9) 15 (2.1)
Anti-hypertension medications 65 (38.9) 70 (39.1) 407 (56.9) 402 (55.7)
Pulmonary (respiratory system)
Medications
16 (9.6) 16 (8.9) 81 (11.3) 87 (12.1)
General cardiac medications 29 (17.4) 40 (22.3) 296 (41.4) 278 (38.5)
Calcium Not collected Not collected 140 (19.6) 139 (19.3)
Calcitonin (mialcalcin) Not collected Not collected 2 (0.3) 1 (0.1)
Vitamin D Not collected Not collected 165 (23.1) 160 (22.2)
Prior surgery to Affected hip, n (%) n = 166 n = 179 n = 714 n = 722
0 (0.0) 1 (0.6) 2 (0.3) 1 (0.1)
Major comorbidities, n (%) n = 166 n = 179 n = 715 n = 722
Osteopenia Not collected Not collected 28 (3.9) 30 (4.2)
Osteoporosis 5 (3.0) 10 (5.6) 114 (15.9) 110 (15.2)
Lung disease 24 (14.4) 15 (8.4) 127 (17.8) 122 (16.9)
Diabetes 24 (14.4) 17 (9.5) 135 (18.9) 145 (20.1)
Ulcers or stomach disease 9 (5.4) 13 (7.3) 49 (6.9) 67 (9.3)
Kidney disease 7 (4.2) 6 (3.4) 71 (9.9) 67 (9.3)
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(207/575) of the excluded patients were not enrolled due to
dementia/cognitive impairment.11
A limitation of this study is that not all demographic-,
comorbidity-, and injury-related data between studies could be
compared to avoid performing multiple comparisons.
Therefore, there are likely other patient characteristics that
may be significantly different between the studies that may not
have been identified. Furthermore, the FAITH and HEALTH
trials were never designed for intertrial comparisons. There
were some differences in the eligibility criteria for each trial,
and although similar data were collected, the 2 trials were not
meant to be compared. Statistical differences between variables
could therefore be misleading. Finally, we are unsure how
prevalent discordant patient enrollment is between randomized
trials evaluating the same injury in orthopaedics.
In conclusion, our study highlights the discrepancy in
patient enrollment of 2 large multicenter prospective random-
ized control trials evaluating the surgical treatment of low-
energy femoral neck fractures, despite using similar inclusion
and exclusion criteria. The patients in the FAITH trial with
displaced femoral neck fractures that were treated with
internal fixation were younger, healthier male subjects with
lower rates of osteoporosis compared with the HEALTH trial
patients treated with arthroplasty. These limitations must be
considered when selecting internal fixation or arthroplasty for
low-energy hip fracture patients aged 50 years and older. This
study highlights an opportunity to form greater investigator
agreement on universal study inclusion and exclusion criteria.
Leaving this at the discretion of each individual surgeon or
investigator may introduce subtle enrollment bias, and greater
TABLE 4. (Continued ) Demographics of Displaced Fracture Patients in FAITH and HEALTH Trials
Characteristic CS, n = 167 SHS, n = 179 THA, n = 718 HA, n = 723
Anemia or other blood disease 4 (2.4) 6 (3.4) 48 (6.7) 55 (7.6)
Depression 12 (7.2) 11 (6.1) 70 (9.8) 84 (11.6)
Cancer 7 (4.2) 7 (3.9) 65 (9.1) 80 (11.1)
Osteoarthritis, degenerative
arthritis
6 (3.6) 11 (6.1) 111 (15.5) 91 (12.6)
Back pain 9 (5.4) 8 (4.5) 64 (9.0) 71 (9.9)
Rheumatoid arthritis 5 (3.0) 1 (0.6) 13 (1.8) 21 (2.9)
Heart disease 28 (16.8) 31 (17.3) 247 (34.6) 249 (34.5)
High blood pressure 68 (40.7) 72 (40.2) 434 (60.7) 443 (61.4)
BMI, body mass index; CS, cancellous screws; HA, hemiarthroplasty; NSAIDS, nonsteroidal anti-inflammatory drugs; SHS, sliding hip screw; THA, total hip arthroplasty.
TABLE 5. Fracture Characteristics of Displaced Fracture Patients in FAITH and HEALTH Trials
Characteristic CS, n = 167 SHS, n = 179 THA, n = 718 HA, n = 723
Fractured hip, n (%) n = 167 n = 179 n = 715 n = 722
Left 91 (54.5) 103 (57.5) 386 (54.0) 386 (53.5)
Right 75 (44.9) 76 (42.5) 329 (46.0) 336 (46.5)
Level of the fracture line, n (%) n = 167 n = 179 n = 715 n = 722
Subcapital 61 (36.5) 74 (41.3) 434 (60.7) 456 (63.2)
Midcervical 86 (51.5) 87 (48.6) 251 (35.1) 230 (31.9)
Basal 19 (11.4) 18 (10.1) 30 (4.2) 36 (5.0)
Garden classification, n (%) n = 167 n = 179 n = 715 n = 722
Garden III (displaced) 128 (76.6) 121 (67.6) 311 (43.5) 320 (44.3)
Garden IV (displaced) 39 (23.4) 58 (32.4) 404 (56.5) 402 (55.7)
Pauwels’ classification, n (%) n = 167 n = 179 n = 714 n = 721
Type I 10 (6.0) 10 (5.6) 70 (9.8) 47 (6.5)
Type II 91 (54.5) 101 (56.4) 404 (56.6) 367 (50.9)
Type III 65 (38.9) 68 (38.0) 240 (33.6) 307 (42.6)
Mechanism of injury, n (%) n = 167 n = 179 n = 715 n = 722
Fall from standing 162 (97.0) 170 (95.0) 696 (97.3) 700 (97.0)
Spontaneous fracture 1 (0.6) 6 (3.4) 16 (2.2) 14 (1.9)
Fall from small height Not collected Not collected 3 (0.4) 8 (1.1)
Other low energy trauma 3 (1.8) 3 (1.7) Not collected Not collected
Additional fractures or injuries, n (%) n = 167 n = 179 n = 714 n = 722
12 (7.2) 9 (5.0) 61 (8.5) 60 (8.3)
CS, cancellous screws; HA, hemiarthroplasty; SHS, sliding hip screw; THA, total hip arthroplasty.
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focus on this aspect of study design is needed. A possible
concern, however, would be that the narrower the study
inclusion criteria, the less generalizable the results would be,
especially when attempting to apply the clinical findings
worldwide. Future work should be directed at the prevention
of study enrollment selection bias by limiting the ability to
exclude patients based on surgeon opinion, especially when
treatment equipoise exists.
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TABLE 6. Comparison of Baseline Characteristics in FAITH and





n = 1441 P*
Age, mean (SD) n = 346 n = 1440 ,0.001
66.9 (11.3) 78.8 (8.4)
Sex, n (%) n = 345 n = 1440 ,0.001
Male 190 (54.9) 431 (29.9)
Female 155 (44.8) 1009 (70.1)
ASA classification, n (%) n = 346 n = 1441 ,0.001
Class I/II 274 (79.2) 652 (45.2)
Class III/IV/V 72 (20.8) 789 (54.8)
Osteoporosis, n (%) n = 346 n = 1441 ,0.001
15 (4.3) 224 (15.6)
*P-values calculated by t-tests and x2 tests.
ASA, American Society of Anesthesiologists.
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